Latest Conference Articles

December 7th 2022, 3:52pm

The Breast Cancer Index test reliably identified premenopausal women undergoing adjuvant endocrine therapy for early-stage, hormone receptor–positive breast cancer who would derive benefit from the addition of ovarian function suppression.

December 7th 2022, 2:30am

San Antonio Breast Cancer Symposium

Non-Hispanic Black patients with hormone receptor–positive/HER2-negative breast cancer were more likely to have worse outcomes vs non-Hispanic White, Asian, and Hispanic patients, according to an analysis of the phase 3 RxPONDER trial.

December 7th 2022, 12:58am

San Antonio Breast Cancer Symposium

A clinically meaningful improvement in invasive disease-free survival and distant relapse-free survival was observed with the addition of adjuvant abemaciclib to endocrine therapy in patients with hormone receptor–positive, HER2-negative, node-positive early breast cancer, according to results of a prespecified overall survival analysis of the monarchE study.

December 7th 2022, 12:46am

San Antonio Breast Cancer Symposium

The addition of 1 year of everolimus to adjuvant endocrine therapy did not demonstrate a statistically significant improvement in invasive disease-free survival or overall survival in patients with high-risk, hormone receptor–positive, HER2-negative breast cancer.

December 6th 2022, 11:51pm

San Antonio Breast Cancer Symposium

The combination of ribociclib plus endocrine therapy yielded a 46% reduction in the risk of disease progression or death compared with chemotherapy in pre/perimenopausal patients with aggressive hormone receptor–positive/HER2-negative advanced breast cancer.

December 6th 2022, 11:47pm

San Antonio Breast Cancer Symposium

Chemotherapy prior to treatment with endocrine therapy could increase the risk of cancer-related cognitive impairment compared with endocrine therapy alone in women with breast cancer, irrespective of menopausal status.

December 6th 2022, 10:59pm

San Antonio Breast Cancer Symposium

Tumor microenvironment of metastasis doorway density—a biomarker of distant metastatic recurrence—is higher in Black women vs White women with estrogen receptor–positive/HER2-negative breast cancer who have residual disease after neoadjuvant chemotherapy.

November 16th 2022, 2:00pm

SITC Meeting

The combination of sotigalimab and pembrolizumab showed encouraging antitumor activity and was well tolerated in the frontline setting of patients with metastatic melanoma.

November 14th 2022, 9:20pm

PER® New York Lung Cancer Symposium

Balazs Halmos, MD, discusses the importance of testing for HER2 mutations and exon 20 insertions, which are emerging new targets in non–small cell lung cancer, and how fam-trastuzumab deruxtecan-nxki meets needs for patients with HER2-mutant disease.

November 14th 2022, 9:10pm

PER® New York Lung Cancer Symposium

Mark G. Kris, MD, discusses the role of immunotherapy in patients with non–small cell lung cancer without driver mutations.

November 14th 2022, 8:55pm

PER® New York Lung Cancer Symposium

In treating patients with locally advanced non–small cell lung cancer, one must consider multiple factors when deciding whether to treat them with immunotherapy or a targeted approach, even though the optimal treatment sequence has yet to be definitively established.

November 14th 2022, 7:55pm

PER® New York Lung Cancer Symposium

Osimertinib remains the preferred first-line therapy for patients with EGFR-mutated non–small cell lung cancer. However, for those with classic EGFR mutations, the day is fast approaching when physicians will add chemotherapy to first-line treatment with the EGFR TKI based on ctDNA results.

November 14th 2022, 7:24pm

PER® New York Lung Cancer Symposium

Investigators are harnessing comprehensive molecular profiling to detect new targets, optimize existing treatment regimens, and develop novel therapies for patients with EGFR and MET exon 20–insertion positive non–small cell lung cancer.

November 13th 2022, 11:00am

SITC Meeting

CYNK-101 demonstrated synergistic activity when used in combination with avelumab through antibody-dependent cellular cytotoxicity against PD-L1–positive non–small cell lung cancer, triple-negative breast cancer, and bladder cancer cell lines, according to preclinical data.

November 12th 2022, 11:00am

PER® Chemotherapy Foundation Symposium (CFS)

Alan L. Ho, MD, PhD, discusses targeted therapies such as TKIs that have demonstrated promising efficacy in multiple patient populations as well as the agents lenvatinib and pembrolizumab.

November 12th 2022, 4:10am

LUGPA Annual Meeting

All patients with prostate cancer, except for those with low-risk or very low-risk localized disease, should be tested for germline mutations, and somatic testing should be done in all patients with metastatic disease as there are therapeutic implications.

November 11th 2022, 11:06pm

LUGPA Annual Meeting

For patients with metastatic castration-resistant prostate cancer who experience disease progression on novel hormonal agents (NHAs) and androgen deprivation therapy, it is important to consider when the NHA was received and whether docetaxel has been administered, as these factors affect downstream options and sequencing.

November 11th 2022, 9:25pm

PER® Chemotherapy Foundation Symposium (CFS)

Benjamin Philip Levy, MD, discusses potential future uses for atezolizumab in non–small cell lung cancer.

November 11th 2022, 9:01pm

LUGPA Annual Meeting

As the role of genetic testing in clinical practice becomes more prevalent for patients with prostate cancer to identify mutations, physicians must consider a variety of factors to determine which patients are candidates for somatic and/or germline testing.

November 11th 2022, 7:25pm

LUGPA Annual Meeting

Because androgen deprivation therapy alone or with docetaxel is not recommended for most patients with metastatic castration-sensitive prostate cancer, a decision must be made between leveraging couplets vs triplets.